Advertisement

Journal of Urban Health

, Volume 79, Issue 1, pp 113–127 | Cite as

Characteristics of injection drug users who utilize tuberculosis services at sites of the baltimore city needle exchange program

  • Elise D. Riley
  • David Vlahov
  • Steven Huettner
  • Peter Beilenson
  • Margaret Bonds
  • Richard E. Chaisson
Original Articles: Various Topics

Abstract

Objective

To describe characteristics of needle-exchange program (NEP) participants who utilized tuberculosis services from an NEP site.

Methods

Between June 1998 and May 1999, tuberculosis services were advertised and offered to Baltimore, Maryland, NEP participants. Demographic and tuberculosis-specific data were collected on participants who self-selected into services. Analyses were based on being tuberculin skin tested, returning for a skin test reading, and testing tuberculin positive.

Results

Among 691 contacts with NEP participants, this service performed 296 tuberculin tests, with an 84% return rate for skin test reading. Participants were 32% female, 87% African American, and 11% employed. Higher frequency of NEP visits was positively associated with requesting tuberculosis services and returning for skin test reading. Among those who returned for skin test reading, longer smoking duration and problems getting food in the past year due to a lack of money were associated with a positive test.

Conclusions

Utilization of a tuberculosis service and high return rates can be achieved among NEP participants without formal recruitment strategies. Frequent exchange appears to facilitate return visits for NEP-based tuberculosis screening, which may imply accessibility for frequent exchangers. More extensive health services at sites of the Baltimore NEP appear to be warranted, with particular attention paid to effectiveness for frequent exchangers.

Keywords

Injection Drug Use Needle-Exchange Program Tuberculosis Prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE, Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945–951.CrossRefGoogle Scholar
  2. 2.
    Galai N, Graham N, Chaisson R, Nelson KE, Vlahov D, Lewis J. Multidrug-resistant tuberculosis. N Engl J Med. 1992;327:1172–1173.CrossRefGoogle Scholar
  3. 3.
    Graham NM, Galai N, Nelson KE, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med. 1996;156:889–894.CrossRefGoogle Scholar
  4. 4.
    Bishai WR, Graham NM, Harrington S, et al. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA. 1998;280: 1679–1684.CrossRefGoogle Scholar
  5. 5.
    Perlman DC, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange program. Am J Public Health. 1997;87:862–863.PubMedGoogle Scholar
  6. 6.
    Salomon N, Perlman DC, Perkins MP, et al. Knowledge of tuberculosis among drug users: relationship to screening return rates. J Subst Abuse Treat. 1999;16:229–235.CrossRefGoogle Scholar
  7. 7.
    Platt J. Heroin Addiction Theory, Research and Treatment. 2nd ed. Malabar, FL: Robert E Krieger Publishing Co.; 1986:221.Google Scholar
  8. 8.
    Riley E, Vlahov D, Safrahein M, Junge B, Beilenson P, Strathdee S. Gender differences in drug use patterns and successful referrals to drug treatment among Baltimore needle exchange participants. Paper presented at: Annual Meeting of the College on Problems of Drug Dependence; June 13–17, 1999; Acapulco, Mexico.Google Scholar
  9. 9.
    Solomon L, Frank R, Vlahov D, Astemborski J. Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Public Health. 1991;81:1285–1290.CrossRefGoogle Scholar
  10. 10.
    Hunter RVM, Rios E, Gomez MA. Persistent intravenous drug abuse and health encounters. Natl Conf Hum Retroviruses Relat Infect. 1995;2:165.Google Scholar
  11. 11.
    Nelson KE, Vlahov D, Solomon L, Cohn S, Munoz A. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Maryland. Arch Intern Med. 1995;155:1305–1311.CrossRefGoogle Scholar
  12. 12.
    Jimenez AD, Johnson WA, Hershow RC, Wiebel WW, Rahimian A. Behavioral and sociocultural factors related to variations in TB treatment compliance among IDUs: an ethnographic study. Paper presented at: Annual Meeting of the American Public Health Association; November 17–21, 1996; New York, New York.Google Scholar
  13. 13.
    Vlahov D, Junge B, Brookmeyer R, et al. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:400–406.CrossRefGoogle Scholar
  14. 14.
    Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education programon return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:455–459.CrossRefGoogle Scholar
  15. 15.
    Malotte CK, Rhodes F, Mais KE. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998;88:792–796.CrossRefGoogle Scholar
  16. 16.
    Malotte CK, Hollingshead JR, Rhodes F. Monetary versus nonmonetary incentives for TB skin test reading among drug users. Am J Prev Med. 1999;16:182–188.CrossRefGoogle Scholar
  17. 17.
    Flynn C, Junge MB, Riley E, Cohn S, Beilenson P, Vlahov D. Selection bias in needle exchange participation as observed in two cohorts of injection drug users. Paper presented at: Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland.Google Scholar
  18. 18.
    Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations. MMWR Morb Mortal Wkly Rep. 1997;46:1–10.Google Scholar
  19. 19.
    American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S247.CrossRefGoogle Scholar
  20. 20.
    Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.PubMedGoogle Scholar
  21. 21.
    O’Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection [see comments]. N Engl J Med. 1994;331:450–459.CrossRefGoogle Scholar
  22. 22.
    Graham NM, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and-seronegative intravenous drug users. JAMA. 1992;267:369–373.CrossRefGoogle Scholar
  23. 23.
    Robert CF, Hirschel B, Rochat T, Deglon JJ. Tuberculin skin reactivity in HIV-seropositive intravenous drug addicts. N Engl J Med. 1989;321:1268.PubMedGoogle Scholar
  24. 24.
    Stoneburner RL, Des Jarlais DC, Benezra D, et al. A larger spectrumof severe HIV-1-related disease in intravenous drug users in New York City. Science. 1988;242:916–919.CrossRefGoogle Scholar
  25. 25.
    Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS. 1987;1:175–182.PubMedGoogle Scholar
  26. 26.
    Rieder HL, Cauthen GM, Comstock GW, Snider DE, Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev. 1989;11:79–98.CrossRefGoogle Scholar
  27. 27.
    Centers for Disease Control and Prevention. Prevention and control of tuberculosis in US communities with at-risk minority populations, and prevention and control of tuberculosis among homeless persons: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1992;41:1–21.Google Scholar
  28. 28.
    Burwen DR, Bloch AB, Griffin LD, Ciesielski CA, Stern HA, Onorato IM. National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. Arch Intern Med. 1995;155:1281–1286.CrossRefGoogle Scholar
  29. 29.
    Tashkin DP, Khalsa ME, Gorelick D, Chang P, Simmons MS, Coulson AH, Gong H Jr. Pulmonary status of habitual cocaine smokers. am Rev Respir Dis. 1992;145:92–100.CrossRefGoogle Scholar
  30. 30.
    Perper JA, Van Thiel DH. Respiratory complications of cocaine abuse. Recent Dev Alcohol. 1992;10:363–377.CrossRefGoogle Scholar
  31. 31.
    Warner EA. Is your patient using cocaine? Clinical signs that should raise suspicion. Postgrad Med. 1995;98:173–176, 180.CrossRefGoogle Scholar
  32. 32.
    Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med. 1993;119:185–193.CrossRefGoogle Scholar
  33. 33.
    Janis EM, Allen DW, Glesby MJ, et al. Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Am J Med. 1996;100:186–192.CrossRefGoogle Scholar
  34. 34.
    Hawkins WE, Latkin C, Mandel W, Oziemkowska M. Do actions speak louder than words? Perceived peer influences on needle sharing and cleaning in a sample of injection drug users. AIDS Educ Prev. 1999;11:122–131.PubMedGoogle Scholar
  35. 35.
    Latkin CA, Knowlton AR, Hoover D, Mandell W. Drug network characteristics as a predictor of cessation of drug use among adult injection drug users: a prospective study. Am J Drug Alcohol Abuse. 1999;25:463–473.CrossRefGoogle Scholar
  36. 36.
    Wiebel WW. Identifying and gaining access to hidden populations. NIDA Res Monogr. 1990;98:4–11.PubMedGoogle Scholar
  37. 37.
    Adler P. Ethnographic research on hidden populations: penetrating the drug world. NIDA Res Monogr. 1990;98:96–112.PubMedGoogle Scholar
  38. 38.
    Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Des Jarlais DC. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep. 1994;109:319–327.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Wolfe H, Marmor M, Maslansky R, et al. Tuberculosis knowledge among New York City injection drug users. Am J Public Health. 1995;85:985–988.CrossRefGoogle Scholar
  40. 40.
    Altice FL, Fleck EM, Selwyn PA, Kaplan EH, Barry M, Gomez J. Provision of health care and HIV counseling and testing for clients of the New Haven Needle Exchange Program (NEP). Paper presented at: Ninth International Conference on AIDS; June 7–11, 1993; Berlin, Germany.Google Scholar
  41. 41.
    Altice F, Khooshnood K, Blankenship KM, Lamberti MP, Selwyn PA. Needle exchange based health services as a comprehensive community prevention program. Paper presented at: Twelfth World AIDS Conference; June 28–July 3, 1998; Geneva, Switzerland.Google Scholar
  42. 42.
    Lum PJ, Guydish JR, Brown C, Allen R. An innovative needle exchange programexclusively for women is well accepted by women injection drug users in San Francisco. Paper presented at: Twelfth World AIDS Conference; 1998; Geneva, Switzerland.Google Scholar

Copyright information

© The New York Academy of Medicine 2002

Authors and Affiliations

  • Elise D. Riley
    • 1
  • David Vlahov
    • 2
    • 3
  • Steven Huettner
    • 2
  • Peter Beilenson
    • 4
  • Margaret Bonds
    • 2
  • Richard E. Chaisson
    • 2
    • 5
  1. 1.Center for AIDS Prevention StudiesUniversity of California at San FranciscoSan Francisco
  2. 2.Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimore
  3. 3.Center for Urban Epidemiologic Studiesthe New York Academy of MedicineNew York
  4. 4.Baltimore City Health DepartmentBaltimore
  5. 5.Department of MedicineJohns Hopkins School of MedicineBaltimore

Personalised recommendations